Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Solution to Defeating Tarrying: Systems for Expanded Efficiency - 2Dominating the Remote Work Way of life: Individual Systems
- 3Israel violated ceasefire with Hezbollah more than 10,000 times, UNIFIL claims
- 4McDonald's is bringing two 'KPop Demon Hunters' meals to McDonald's. Here's what they include and when they launch.
- 56 Robot Vacuum Cleaners for Easy Home Cleaning
- Popular Home Rug Series For You
- HGV driver recruited others to smuggle migrants
- Advocacy groups react after Mattel introduces 1st Barbie doll with autism
- Regeneron's experimental therapy combo effective in untreated cancer patients
- Become the best at Discussion: 6 Procedures for Progress
- Stunning new James Webb Space Telescope images reveal 'hidden' stars being born
- Extraordinary Guinness World Records That Will Astound You
- Must-See Attractions in France
- ByHeart infant formula recall tied to botulism outbreak puts parents on edge
